Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Encouraging

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 24, 2022 5:28pm

143 Views

Post# 34543316

RE:RE:RE:RE:RE:RE:Encouraging

As I noted at the start of this debate today, I think the company has already basically told us they have proof of concept/partial tumor regression/stable disease. And I noted that the scientists among us would not likely agree to that, understandably so, from a technical perspective until they got the test results they need to see it. For investors, however, I think we can be encouraged by how the company is acting and with what they shared in the corporate presentation that we will have a lot to look forward to as TH-1902 progresses through the FDA trials and much to continue to debate as that happens. Somethign positive has almost certainly happened in the phase 1a trial and, while we do not know the specifics of it, whatever it is will no doubt be an encouragement to us all, even the scientists among us.

palinc2000 wrote: Now I see the difference between a good sign and proof of concept
Thank you so much JMF you are the greatest!!! You are the best fact based scientist on this mb

jfm1330 wrote: This is as close as having the proof they have proof of concept for TH19P01. Why would you start the search to hire a RNA specialist if you are not sure your peptide conjugate works at entering cells by binding to sortilin? It is not 100% sure they have the proof of concept, but it is close. Add that to the feedback from the management's meetings with big investors. It also shows a willingness to develop full proprietary PDCs in the future. RNA sequences that can be used as siRNA are easy to identify. What is hard is to get them inside the cells intact and free.

Wino115 wrote: Would they bother hiring scientist at the cutting edge around ways to possibly kill tumor cells if they weren't extremely confident of the POC signs they've seen so far. I just don't think they would. To me, it's one more positive around the concept showing that it works. As for efficacy, we'll have to see, but it seems to have moved from conceptual invivo to human proof at least around the peptide, targeting, internalization part. All good.